Papa R, Natoli V, Caorsi R, Minoia F, Gattorno M, Ravelli A. Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases.
Pediatr Rheumatol Online J 2020;
18:56. [PMID:
32653009 PMCID:
PMC7353681 DOI:
10.1186/s12969-020-00450-9]
[Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2020] [Accepted: 07/03/2020] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND
Hyperferritinemic syndromes are systemic inflammatory disorders characterized by a dysfunctional immune response, which leads to excessive activation of the monocyte-macrophage system with hypercytokinemia and may pursue a rapidly fatal course.
CASE PRESENTATION
We describe two patients of 11 and 9 years of age with hyperferritinemic syndromes, one with impending macrophage activation syndrome (MAS) and one with overt MAS, who were refractory or intolerant to conventional therapies, but improved dramatically with canakinumab.
CONCLUSIONS
Our report indicates that canakinumab may be efficacious in the management of hyperferritinemic syndromes, including MAS.
Collapse